The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma.
Multiple myeloma (MM) is an incurable plasma cell neoplasm with an incidence of 100 patients per year in Singapore. Major advances have been made in the diagnosis, risk stratification and treatment of MM in the recent past. The reclassification of a subset of patients with smouldering MM, based on high-risk biomarkers, and the development of the revised international staging system are among the key new developments in diagnosis and staging. The use of novel agent-based treatment has resulted in significant improvements in the survival and quality of life of many patients with MM. Determining the optimal use of proteasome inhibitors, immunomodulators and, more recently, monoclonal antibodies is an area of ongoing investigation. In this guideline, we aim to provide an overview of the management of MM, incorporating the latest developments in diagnosis and treatment.
Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore.
Sanjay
S
de Mel
Department of Haematology, Singapore General Hospital, Singapore.
Yunxin
Y
Chen
Department of Haematology, Singapore General Hospital, Singapore.
Sathish Kumar
SK
Gopalakrishnan
Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore.
Melissa
M
Ooi
Division of Oncology Pharmacy, National University Cancer Institute, National University Health System, Singapore.
Constance
C
Teo
Raffles Cancer Centre, Raffles Hospital, Singapore.
Daryl
D
Tan
Department of Haematology, Singapore General Hospital, Singapore.
Min Li Claire
ML
Teo
Department of Haematology, Tan Tock Seng Hospital, Singapore.
Allison Cy
AC
Tso
Department of Haematology, Tan Tock Seng Hospital, Singapore.
Lian King
LK
Lee
Department of Haematology, Singapore General Hospital, Singapore.
Chandramouli
C
Nagarajan
Department of Haematology, Singapore General Hospital, Singapore.
Yeow Tee
YT
Goh
Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore.
Wee Joo
WJ
Chng
D000368:Aged; D000911:Antibodies, Monoclonal / Q000737:chemistry; D014408:Biomarkers, Tumor; D005260:Female; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000592:standards*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000628:therapy*; D017410:Practice Guidelines as Topic; D046988:Proteasome Endopeptidase Complex; D011788:Quality of Life; D012306:Risk; D012846:Singapore; D012955:Societies, Medical; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D046988:Proteasome Endopeptidase Complex
Singapore; evidence-based; guideline; multiple myeloma